HealthCor Management L.P. lowered its holdings in Five Prime Therapeutics Inc (NASDAQ:FPRX) by 90.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 101,000 shares of the biotechnology company’s stock after selling 909,930 shares during the period. HealthCor Management L.P. owned approximately 0.30% of Five Prime Therapeutics worth $2,214,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Franklin Street Advisors Inc. NC purchased a new stake in shares of Five Prime Therapeutics in the fourth quarter valued at $548,000. AXA acquired a new position in shares of Five Prime Therapeutics in the third quarter worth $5,441,000. ARK Investment Management LLC increased its stake in shares of Five Prime Therapeutics by 96.4% in the fourth quarter. ARK Investment Management LLC now owns 43,215 shares of the biotechnology company’s stock worth $947,000 after acquiring an additional 21,211 shares during the last quarter. Altrinsic Global Advisors LLC acquired a new position in shares of Five Prime Therapeutics in the fourth quarter worth $1,754,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Five Prime Therapeutics in the third quarter worth $2,577,000. Institutional investors own 74.94% of the company’s stock.
Several equities analysts have commented on the stock. BidaskClub downgraded shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Zacks Investment Research downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, March 2nd. Nomura lowered their price target on Five Prime Therapeutics from $94.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, February 28th. BMO Capital Markets lowered their price target on Five Prime Therapeutics from $75.00 to $60.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 28th. Finally, ValuEngine downgraded Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Three analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Five Prime Therapeutics presently has a consensus rating of “Hold” and an average target price of $47.20.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.